Magnasense AB (MAGNA.ST)
- Previous Close
0.0831 - Open
0.0800 - Bid 0.0828 x --
- Ask 0.0829 x --
- Day's Range
0.0800 - 0.0889 - 52 Week Range
0.0506 - 0.4745 - Volume
324,735 - Avg. Volume
1,941,399 - Market Cap (intraday)
52.977M - Beta (5Y Monthly) 2.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs in Sweden and internationally. The company develops a home testing platform for oral health, therapeutic drug monitoring, and infectious diseases. Its product line includes the Veritope technology with intact natalizumab in multiple sclerosis; and the MagniaReader which is utilized in research and veterinary applications. The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024. Magnasense AB was incorporated in 2019 and is headquartered in Lund, Sweden.
www.magnasense.comRecent News: MAGNA.ST
View MorePerformance Overview: MAGNA.ST
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAGNA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAGNA.ST
View MoreValuation Measures
Market Cap
53.62M
Enterprise Value
97.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
1.21k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-68.36%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-49.63M
Diluted EPS (ttm)
-0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
283k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-44.37M